drugset / Trial / NCT00139568

An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation

NCT00139568

Phase 3 Completed 600 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

Tegaserod is an aminoguanidine indole compound and a member of a new class of 5-hydroxytryptamine (5-HT) agonists. Activation of 5-HT4 receptors triggers the release of neurotransmitters from the enteric nerves which in turn stimulate contractility and peristalsis. This study will investigate the efficacy and safety of tegaserod against chronic constipation in a Chinese population of adult men and women

Timeline

Start
2005-02
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegaserod Small molecule 6 mg Oral

Indications